PIM1 is aberrantly expressed in several cancers, and its pharmacological inhibition in breast cancer, T-ALL cell lines, adult T-cell leukemia, and T-cell lymphoma (ATL) is therapeutically effective [39, 40]. Here, PIM1 is linked to T-cell non-Hodgkin lymphoma.